Antisense oligodeoxynucleotide directed against c-myb has anticancer activity and potentiates the antiproliferative effect of conventional anticancer drugs acting by different mechanisms in human colorectal cancer cells

Tumor Biology

Volumn 24, Issue 5, 2003, Pages 241-257

  Abaza, Mohamed Salah I ^a   Al Attiyah, Rajaa J ^a   Al Saffar, Amal M ^a   Al Sawan, Shorooq M ^a   Moussa, Naguib M ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

c myb; Colorectal cancer; Cytotoxic drugs; Phosphorothioate oligodeoxynucleotide

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; DOXORUBICIN; FLUOROURACIL; MESSENGER RNA; PACLITAXEL; PHOSPHOROTHIOIC ACID; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; GENE; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; ONCOGENE C MYB; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS;

EID: 1542283682     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076139     Document Type: Article

References (51)

1. Alison MR, Sarraf CE: The role of growth of factors in gastrointestinal cell proliferation. Cell Biol Int 1994;18:1-10.
2. Dainer PM, Dipiro CR, Richards CS: Colorectal cancer: New pharmacologic strategy for prevention and treatment. Mod Med Middle East 1993;10:54-66.
3. Mansour SL, Thomas KR, Capecchi MR: Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: A general strategy for targeting mutations to non-selectable genes. Nature 1988;336:348-352.
4. Wadler S, Haynes H, Schechner R, Rosenblit A, Wiernik PH: Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-flurorouracil and recombinant interferon alpha-2a in patients with advanced malignancies. Invest New Drugs 1996;13:315-320.
5. Kjaer M: Combining 5-fluorouracil with interferon-alpha in the treatment of advanced colorectal cancer: Optimism followed by disappointment. Anticancer Drugs 1996;7:35-42.
6. Lopez M, Di Lauro L, Paoletti G, Santini S, Gandolfo GM, Vitelli G, Frasca AM, Ameglio F, Rasi G, Garaci F: Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: Clinical and immunological effects. Oncology 1995;6:1011-1017.
7. Chang AE, Cameron MJ, Sondak VK, Geiger JD, Vander Woude Dl: A phase II trial of interleukin-2 and interferon-alpha in the treatment of metastatic colorectal carcinoma. J. Immunother Emphasis Tumor Immunol 1995;18:253-262.
8. Cascinu S, Alessandroni P, Rossi D, Del Ferro E, Fedeli A, Casadei V, Catalano G: Multimodal biochemical modulation of 5-fluorouracil by leucovorin, methotrexate and interferon alpha in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 1996;38:385-386.
9. Vermeulen PB, Dirix LY, Pelgrims G, Van Oosterom AT: 5-fluorouracil/ leucovorin/interferon alpha 2a in patients with advanced colorectal cancer. Cancer 1995;76:528-530.
10. Pavlidis N, Nicolaides C, Athanassiadis A, Beriatuou K, Skarlos D, Giannakakis T, Kosmidis P, Karvounis N, Fountzilas G: Phase II study of 5-fluorouracil and interferon-gamma in patients with metastatic colorectal cancer. Oncology 1996;53:159-162.
11. Moore MJ, Kaizer L, Erlichman C, Myers R, Feld R, Thiessen JJ, Fine SA: Clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alpha in advanced colorectal cancer. Cancer Chemother Pharmacol 1995;34:86-90.
12. Kohne CH, Wilke H, Hiddemann W, Bokemeyer C, Lohrmann HP, Bodenstein H, Preiss J, Rauschecker H, Hill H, Kaufer C, Fischer JT, Ohl U, Urganitz D, Balleisen L, Schmoll HJ: Phase II evaluation of 5-fluorouracil plus folinic acid and alpha 2-b interferon in metastatic colorectal cancer. Oncology 1997;54:9-101.
13. Cascinu S, Del Ferro E, Ligi M, Catalano G: A phase I trial of 5-fluorouracil, leucovorin and interferon alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma. Anticancer Drugs 1996;7:520-524.
14. Tagliaferri P, Barile C, Caraglia M, Guarrasi R, Morelli D, Ricciardi B, Martignetti A, Libera MT, Matano E, Della Vecchia A, Catalano G, Famiani M, Palmieri G, Correale P, Bianco AR: Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration: Antitumor activity and immunomodulatory effects. Am J Clin Oncol 1998;21:48-53.
15. Koshiji M, Adachi Y, Taketani S, Takeuchi K, Hioki K, Ikehara S: Mechanisms underlying apoptosis induced by combination of 5-fluorouracil and interferon-gamma. Biochem Biophys Res Commun 1997;240:376-381.
16. Woll PJ, Pettengell R: Interferons in oncology. Br J Clin Pract 1997;51:111-115.
17. Majello B, Kenyon LC, Dalla Favera R: Human c-myb protooncogen: Nucleotide sequence of c-DNA and organization of the genomic locus. Proc Natl Acad Sci USA 1986;83:9636-9640.
18. Melani C, Rivoltini L, Parmiani G, Calabretta B, Colombo P: Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb. Cancer Res 1991;51:2897-2901.
19. Kraehn GM, Utikal M, Greulich KM, Bezold G, Kaskel P, Leiter U, Peter RU: Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br J Cancer 2001;84:72-79.
20. Lama G, Angelucci C, Recchia F, Sica G: Combined effects of 13-cis-retinoic acid, tamoxifen and interferon on the growth of human breast cancer cells. Cancer Lett 1996;100:181-189.
21. Lam PK, To EWH, Chan ESY, Liew CT, Lung IWH, King WK: In vitro modulation of head and neck cell growth by human recombinant interferon α and 13-cis-retinoic acid. Br J Biomed Sci 2001;58:226-229.
22. Calabretta B: Inhibition of protooncogene expression by antisense oligodeoxynucleotides: Biological and therapeutic implications. Cancer Res 1991;51:4505-4510.
23. Negroni A, Scarpa S, Romeo A, Ferraris S, Modesti A, Raschella G: Decrease of proliferation rate and induction of differentiation by a MYCN antisense DNA oligomer in a human neuroblastoma cell. Cell Growth Diff 1991;2:511-518.
24. Citro G, Szczylik C, Ginobbi P, Zupi G, Calabretta B: Inhibition of leukemia cell proliferation by folic acid polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL60 cells. Br J Cancer 1994;69:463-467.
25. Shen-Ong GLC: The c-myb oncogene. Biochim Biophys Acta 1990;32:49-52.
26. Schmidt M, Koller R, Haviernik P, Bies J, Maciag K, Wolf L: Deregulated c-myb expression in murine leukemias prevents the up-regulation of p15INK4b normally associated with differentiation. Oncogene 2001;6205-6214.
27. Hogg A, Schirm S, Nakagoshi H, Bartley P, Ishii S, Bishop JM, Gonda TJ: Inactivation of a c-myb/estrogen receptor fusion protein in transformed primary cells leads to granulocyte/macrophage differentiation and down-regulation of c-kit but not c-myc or cdc2. Oncogene 1997;15:2885-2898.
28. Schmidt M, Nazarov V, Stevens L, Watson R, Wolff L: Regulation of the resident chromosomal copy of c-myc by c-myb is involved in myeloid leukemogenesis. Mol Cell Biol 2000;20:1970-1981.
29. Gewirtz AM: Myb targeted therapeutics for the treatment of human malignancies. Oncogene 1999;18:3056-3062.
30. 2 and suppresses apoptosis in myeloid cells. Genes Dev 1996;10:2720-2731.
31. Taylor D, Badiani P, Weston K: A dominant interfering Myb mutant causes apoptosis in T cells. Genes Dev 1996;10:2732-2744.
32. Thompson EB: The many roles of c-myc in apoptosis. Annu Rev Physiol 1998;60:575-600.
33. Reiss K, Ferber A, Travali S, Porcu P, Phillips PD, Baserga R: The protooncogene c-myb increases the expression of insulin-like growth factor 1 and insulin-like growth factor 1 receptor messenger RNAs by transcriptional mechanism. Cancer Res 1991;51:5997-6000.
34. Ramsay RG, Thompson MA, Haymand JA, Reid G, Gonda TJ, Whitehead RH: Myb expression is higher in malignant human melanoma, colonic carcinoma and premalignant adenomatous polyps than in normal mucosa. Cell Growth Diff 1992;3:723-730.
35. Calabretta B, Nicolaides NC: c-myb and growth control: Critical reviews in eukaryotic gene expression. Gene Expr 1992;2:225-235.
36. Lyon J, Robinson C, Watson R: The role of Myb proteins in normal and neoplastic cell proliferation. Crit Rev Oncog 1994;5:373-388.
37. Melani C, Rivolini L, Parmiani G, Calabretta B, Colombo MP: Inhibition of proliferation by c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb. Cancer Res 1991;1:2897-2901.
38. Fearon ER, Vogelstein BA: A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
39. Prins J, De Vrie EGE, Proffit RT, Mulder NH: The effect of antisense c-myc oligonucleotides on proliferation and cisplatin (CDDP) sensitivity of a small cell lung carcinoma cell line (GLC4) and its 5-6X cDDP-resistant subline (GLC4-cDDP). Proc Am Assoc Cancer Res 1993;34:279-283.
40. Stein CA, Subasinghe C, Shinozuka K, Cohen JE: Physicochemical properties of phosphorothioate oligodeoxy-nucleotides. Nucleic Acids Res 1988;16:3206-3221.
41. Agrawal S, Temsamani J, Tang YJ: Pharmacokinetics, biodistribution and stability of oligodeoxynucleotides phosphorothioate in mice. Proc Natl Acad Sci USA 1991;88:7595-7599.
42. Hijiya N, Zhang J, Ratajczak MZ, Kant JA, Deriel K, Herlyn M, Zong G, Gewirtz AM: Biologic and therapeutic significance of Myb expression in human melanoma. Proc Natl Acad Sci USA 1994;91:4499-4503.
43. Ratajczak MZ, Kant JA, Luger S-M, Hijiya N, Zhang J, Zon G, Gewirtz AM: In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 1992;89:11823-11827.
44. Del Bufalo D, Cucco C, Leonetti C, Citro G, D'Agnano I, Benassi M, Geiser T, Zon G, Calabretta B, Zupi G: Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo. Br J Cancer Res 1996;74:387-393.
45. Funato T: Circumventing drug resistance in human tumors by antisense ribozyme. Gan To Kagaku Ryoho 1994;21:336-342.
46. Nieborowska-Skarska M, Nakashima M, Patajczak M, Steplewski Z, Calabretta B, Skorski T: Oncogene targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: A new approach for tumor treatment? Folia Histochem Cytobiol 1994;32:35-40.
47. Deluca A, Selvam MP, Sandomenico C, Pepe S, Raffaele Bianco A, Ciardiello F, Salomon DS, Normanno N: Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells. Int J Cancer 1997;73:277-282.
48. Ciardiello F, Bianco R, Damiano V, Fontianini G, Caputo R, Pomatico G, De Placido S, Raffaele Bianco A, Medelsohn J, Tortora G: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000;6:3739-3749.
49. 2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. Int J Cancer 2000;88:804-809.
50. Nita ME, Ono-Nita SK, Tsuno N, Tominaga O, Takenoue T, Sunami E, Kitayama J, Nakamura Y, Nagawa H: BCl-X(L) antisense sensitizes human colon cancer cell line to 5-fluorouracil. Jpn Cancer Res 2000;91:825-832.
51. Tortora G, Bianco R, Damiano V, Fontanini G, De Placido S, Bianco AR, Ciardiello F: Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production. Clin Cancer Res 2000;6:2506-2512.